CENTER VALLEY, Pa., Sept. 18, 2018 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today it is hosting an upcoming live webinar entitled "Mechanically Enhanced Colonoscopy – Master the Art of Unfolding", presented by Dr. Doug Rex. The webinar will be presented on September 20, 2018 at 5:00 PM EST.
Recently, Dr. Rex led a multi-center, randomized study on emerging colonoscopy technologies. The study, published in Volume 88, No. 2 : 2018 of the prestigious GIE Journal of the American Society of Gastroenterologists, revealed that the use of ENDOCUFF VISION® produced gains in adenoma detection, even in the hands of physicians who are very skilled with standard instruments lacking adjunctive devices and with a high adenoma detection rate (ADR). ADR was 14% higher compared to HD colonoscopy without an adjunctive device.
Placed on the distal tip of a colonoscope, ENDOCUFF VISION's unique hinged arms fall flat against the shaft of the scope to reduce slippage during forward advancement. During withdrawal, the arms flare out and stabilize the tip, gently stretching the mucosal surface to allow the physician thorough inspection of the anatomy during the search for polyps. The study results demonstrate that the design of ENDOCUFF VISION is superior as a mucosal exposure device for colonoscopy.
Colorectal cancer (CRC) is the second most common cause of cancer-related mortality. ENDOCUFF VISION has been shown to improve adenoma detection rates which at times, can be precursors to cancer. For each 1% increase in adenoma detection, there is a 3% reduction in the risk of interval cancer and a 5% decrease in the risk of a fatal interval colorectal cancer1.
"I am excited to discuss the results of the multi-center study using ENDOCUFF VISION during this live webinar," said Dr. Doug Rex, a gastroenterologist and Professor of Medicine at Indiana University. "ENDOCUFF VISION provides many benefits to both patients and physicians, including its statistically significant and clinically relevant improvement in ADR, as compared with unassisted colonoscopy. It can be very effective in the diagnosis and treatment of colon cancer."
ENDOCUFF VISION is a 510(k) cleared, second generation, single-use device designed to give an optimal view of the entire colon throughout a colonoscopy procedure. As of 2016, the ENDOCUFF was discontinued and replaced with the next generation, ENDOCUFF VISION. Compared to the original ENDOCUFF, ENDOCUFF VISION has a single row of longer arms. These changes deliver yet more tip control throughout the colon without compromising intubation and improving loop management. Olympus Corporation of the Americas is the exclusive distributor of the device in the U.S. and Canada.
About Olympus Medical Systems Group
Olympus Medical Systems Group, a division of global technology leader Olympus, develops solutions for healthcare professionals that help improve clinical outcomes, reduce overall costs and enhance quality of life for their patients. By enabling less invasive procedures, innovative diagnostic and therapeutic endoscopy, and early stage lung cancer evaluation and treatments, Olympus is transforming the future of healthcare. For more information visit Olympus at www.medical.olympusamerica.com.
1 The Olympus ENDOCUFF received FDA 510(k) clearance in 2016 for the claim that the device results in a statistically significant and clinically relevant improvement in adenoma detection rate (ADR), as compared with unassisted colonoscopy, due to its design which enables manipulation of bowel folds for maximized visualization of mucosa.
SOURCE Olympus Medical Systems Group